Research programme: autosomal dominant polycystic kidney disease therapeutics - Mironid/University of Sheffield
Alternative Names: Autosomal dominant polycystic kidney disease therapeutics - Mironid/University of SheffieldLatest Information Update: 10 Nov 2023
At a glance
- Originator Mironid; University of Sheffield
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Autosomal dominant polycystic kidney disease
Most Recent Events
- 13 Sep 2023 Preclinical trials in Autosomal dominant polycystic kidney disease in Scotland (unspecified route), before September 2023 (Mironid pipeline, September 2023)
- 13 Sep 2023 Pharmacodynamics data from preclinical trial in Autosomal dominant polycystic kidney disease were released by Mironid
- 13 Sep 2023 Mironid plans clinical studies in Autosomal dominant polycystic kidney disease